Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
XLO

XLO - Xilio Therapeutics, Inc. Stock Price, Fair Value and News

$0.61-0.01 (-1.61%)
Market Closed

Price Targets

XLO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XLO Price Action

Last 7 days

1.7%

Last 30 days

-6.1%

Last 90 days

-23.7%

Trailing 12 Months

-17.6%

XLO RSI Chart

XLO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XLO Valuation

Market Cap

32.0M

Price/Earnings (Trailing)

-0.55

Price/Sales (Trailing)

5.79

Price/Free Cashflow

-1.82

XLO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

XLO Fundamentals

XLO Revenue

Revenue (TTM)

6.3M

Rev. Growth (Yr)

742.51%

Rev. Growth (Qtr)

135.85%

XLO Earnings

Earnings (TTM)

-58.5M

Earnings Growth (Yr)

-16.17%

Earnings Growth (Qtr)

-2.8%

XLO Profitability

Return on Equity

722.53%

Return on Assets

-43.75%

Free Cashflow Yield

-54.89%

XLO Investor Care

Shares Dilution (1Y)

19.43%

Diluted EPS (TTM)

-0.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240006.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About Xilio Therapeutics, Inc.

XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEhttps://xiliotx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES84

Xilio Therapeutics, Inc. Frequently Asked Questions

XLO is the stock ticker symbol of Xilio Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Xilio Therapeutics, Inc. is 32.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check XLO's fair value in chart for subscribers.

The fair value guage provides a quick view whether XLO is over valued or under valued. Whether Xilio Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Xilio Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XLO.

As of Wed Jan 28 2026, XLO's PE ratio (Price to Earnings) is -0.55 and Price to Sales (PS) ratio is 5.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XLO PE ratio will change depending on the future growth rate expectations of investors.